Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Erik Volz et al.
Summary: The study suggests a positive selection for the SARS-CoV-2 spike protein variant D614G in the UK, but no evidence of differences in COVID-19 mortality or clinical severity in patients infected with this variant. 614G is associated with higher viral load and younger age of patients compared to 614D.
Article
Multidisciplinary Sciences
Lewis F. Buss et al.
Summary: Research indicates that the attack rate of COVID-19 in Manaus, the capital of Amazonas state in northern Brazil, reached 66% in June 2020, rising to 76% by October, higher than the estimated attack rate of 29% in Sao Paulo, southeastern Brazil, during the same period.
Article
Public, Environmental & Occupational Health
Koen B. Pouwels et al.
Summary: This study in England found significant changes in the number of individuals testing positive for SARS-CoV-2 and risk factors for positivity over time from April to November 2020. Important risk factors for testing positive varied between the first and second waves, with age being a key driver of increased positivity rates in the second wave. Continued monitoring for SARS-CoV-2 in the community will be important for managing the COVID-19 pandemic moving forwards.
LANCET PUBLIC HEALTH
(2021)
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article
Infectious Diseases
Alexandre Gaymard et al.
Summary: The emergence of the SARS-CoV-2 variant 201/501Y.V1 in France is concerning due to its increased transmissibility. Recent data shows that this variant is 52-69% more transmissible compared to previously circulating lineages, with a prevalence of 6.9% in the Paris region.
Article
Immunology
Michael Kidd et al.
Summary: Analysis of recent test data shows that samples containing the SARS-CoV-2 variant B1.1.7 with mutation Delta 69/70 exhibit S gene target failure (SGTF) in ThermoFisher TaqPath RT-qPCR. Samples with SGTF profile are more likely to have higher viral loads, indicating higher infectivity and rapid spread of this variant.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Editorial Material
Medicine, General & Internal
Ester C. Sabino et al.
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.
Article
Biochemistry & Molecular Biology
Nicole L. Washington et al.
Summary: The highly transmissible B.1.1.7 variant of SARS-CoV-2, first identified in the United Kingdom, has been spreading in the United States with multiple introductions as early as late November 2020. The variant shows a logistic growth rate with roughly weekly doubling and increased transmission, requiring immediate action to minimize COVID-19 morbidity and mortality.
Article
Medicine, General & Internal
Eleftheria Vasileiou et al.
Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.
Article
Medicine, General & Internal
Katherine R. W. Emary et al.
Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: Studies have shown that the SARS-CoV-2 B.1.1.7 lineage is more transmissible and may cause more severe illness compared to pre-existing variants.
Article
Multidisciplinary Sciences
Erik Volz et al.
Summary: Genetic and testing data from England indicate that the SARS-CoV-2 variant B.1.1.7 has a transmission advantage over other lineages, showing a rapid expansion during autumn 2020. Analysis of S gene target failures (SGTF) in community-based diagnostic PCR testing suggests that B.1.1.7 is more transmissible than non-variant of concern lineages and has a significant transmission advantage, with a reproduction number 50% to 100% higher. Additionally, cases of B.1.1.7 appear to include a larger share of under 20-year-olds compared to non-variant cases.
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Nuno R. Faria et al.
Summary: A new variant of concern, P.1, with 17 mutations including three spike protein mutations associated with increased binding to human ACE2 receptors, emerged in Manaus, Brazil between November 2020 and January 2021. Molecular analysis suggests P.1 may be 1.7- to 2.4-fold more transmissible and that previous infection may provide 54 to 79% protection against P.1 infection compared to other lineages. Enhanced global genomic surveillance of such variants is crucial for pandemic response.
Article
Virology
Javier Martin et al.
